To determine whether maternal treatment with sildenafil improves perinatal outcomes in pregnancies with severe IUGR. IUGR most commonly occurs due to poor implantation leading to placental hypoxia with elective preterm delivery being the only management option. IUGR and associated prematurity expose the fetus 1 neonate to significant mortality and morbidity. Sildenafil potentiates the effect of nitric oxide and thus may cause vasodilatation of incompletely remodelled maternal spiral arteries. The potential increase in uteroplacental perfusion may result in improved placental function fetal growth and well-being. Methods: This was a randomised, double blind, placebo controlled trial of oral sildenafil 25mg three times a day versus placebo for the treatment of singleton pregnancies between 22+0 and 29+6 weeks of gestation complicated by severe IUGR defined as an AC or EFW less than 10th centile and absent or reversed umbilical artery Doppler studies. Treatment was given until 31+6 weeks or delivery, whichever came sooner. The primary outcome was prolongation of pregnancy by one-week with sildenafil. Results: 135 women (70 sildenafil and 65 placebo) were recruited to the STRIDER study between November 2014 and July 2016. Median (IQR) gestational age at randomisation was 25.4 weeks (24, 27.5) with a median EFW of 444.5g (344, 608). 93 (69%) had absent and 42 (31%) reversed EDF in the UA. Median (IQR) randomisation to delivery was 15 (6, 23) days with sildenafil and 18 (8, 30) days with placebo (p = 0.164). There was no difference in gestational age strata: <26+0 weeks [sildenafil 18 days (10, 27) versus placebo 19 days (13, 29)] or ≥26+0 weeks [sildenafil 14 days (6, 21) versus placebo 13 days (5, 21)]. There were 43 (31.9%) fetal deaths (sildenafil = 22, placebo = 21) and 17 (18%) neonatal deaths (sildenafil =10, placebo =7). There were no reported maternal serious adverse events associated with sildenafil. Conclusions: Sildenafil does not prolong gestation when compared to placebo in severe IUGR. We found no evidence of beneficial effect for sildenafil on survival or short-term neonatal adverse outcomes. Objectives: To evaluate the effects of maternal corticosteroids Betamethasone (BM) and Dexamethasone (DM) on fetal cardiovascular and behavioural status in the first 7-10 days after administration, as measured by ultrasound and cardiotocography (CTG). Methods: Two-centre nested observational study of multicentre, blinded randomised trial of BM versus DM administered to women at risk of preterm birth <34 weeks (ACTRN: 12608000631303). Umbilical artery (UA), middle cerebral artery (MCA), ductus venosus (DV), uterine artery Doppler, myocardial performance index (MPI), biophysical profile (BPP) and CTG were performed pre-steroid then 1, 2, 4, and 7-10 days post-steroid, with assessments blinded to type of steroid treatment. Within and between-subjects repeated measures analysis was performed, by time and type of steroid. Results: 47 fetuses were examined (39 singleton, 4 DCDA twin, 4 MCDA twin) February 2012-2013; 23 received BM and 20 DM. Thirteen pregnancies (30%) had pre-steroid fetal concerns (estimated weight<10th centile and/or abnormal UA/MCA Doppler). Few significant differences were seen pre versus post-steroid. Mean DV pulsatility index (PI) and right MPI both decreased 15-20% at 1 day, returning to within 10% of baseline by 2 days. Mean BPP decreased 3-5% Day 1-2, due to more fetuses with no breathing seen post-steroid, then increased 5-10%. No significant difference in ultrasound or CTG parameters was seen by BM vs. DM treatment. Conclusions: In fetuses at risk of preterm birth but mostly normal baseline fetal status, there were no major effects of corticosteroids on ultrasound/CTG measures. The modest, transient changes in DV PI, right MPI and BPP reinforce the need to note any recent corticosteroid administration when clinically assessing fetal wellbeing measures, and not to rely on single measures for timing of birth decisions soon after corticosteroids are given. Type of corticosteroid (BM vs. DM) did not appear to influence fetal cardiovascular status.
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